



## Commercial PA Criteria Effective: December 12, 2024

**Prior Authorization:** Cobenfy

**Products Affected:** Cobenfy (Xanomeline and Trospium Chloride) Oral Capsules

**Medication Description:** Cobenfy, a combination of xanomeline (a muscarinic agonist) and trospium chloride (a muscarinic antagonist), is indicated for the treatment of schizophrenia in adults.

**Covered Uses:** treatment of schizophrenia in adults.

**Exclusion Criteria:**

1. Urinary retention
2. Moderate or severe hepatic impairment
3. Gastric retention
4. History of hypersensitivity to Cobenfy or trospium chloride
5. Untreated narrow-angle glaucoma

**Required Medical Information:**

1. Diagnosis
2. Medication History

**Prescriber Restriction:** The medication is prescribed by, or in consultation with, a psychiatrist or a physician who specializes in the treatment of schizophrenia .

**Age Restriction:** Patient must be  $\geq 18$  years of age.

**Coverage Duration:** 12 months

**Other Criteria:**

### Initial Approval Criteria

1. **Schizophrenia.** Approve if the patient meets the following criteria (A, B, C **AND** D)
  - A. Patient has a diagnosis of schizophrenia **AND**
  - B. Patient has tried two other novel (atypical) antipsychotics **AND**  
*Note: Examples of novel (atypical) antipsychotics include risperidone tablets/orally disintegrating tablets (ODT) [Risperdal, generics], Fanapt tablets, olanzapine tablets/ODT (Zyprexa/Zydis, generics), quetiapine tablets (Seroquel, generics), quetiapine extended-release tablets (Seroquel XR, generics), aripiprazole tablets (Abilify, generics), paliperidone ER tablets (Invega, generics), ziprasidone capsules (Geodon, generics), Latuda tablets, Rexulti tablets, asenapine sublingual tablets (Saphris, generics), Caplyta.*
  - C. Cobenfy will be used as monotherapy in the treatment of schizophrenia (i.e not used in combination with

December 2024



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



first or second- generation antipsychotics) **AND**

- D. The medication is prescribed by, or in consultation with, a psychiatrist or a physician who specializes in the treatment of schizophrenia.

**References:**

1. Cobenfy™ capsules [prescribing information]. Princeton, NJ: Bristol Myers Squibb; September 2024.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	12/12/2024

